PrimaryLogo_Mango-05.png
MangoRx to Introduce Oral Semaglutide and Tirzepatide in Response to Increasing Patient Demand for GLP-1 Medications
21 mai 2024 08h30 HE | Mangoceuticals, Inc.
Formulations to be marketed as “Slim” and “Trim” as an Oral Dissolvable Tablet (ODT) Dallas, TX, May 21, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”),...